Global Autologous Cell Therapy Market: Development of Bone Marrow-based Products Ensures Whopping 21.9% CAGR by 2024

Autologous cell therapy refers to infusion or transfer of human tissue or cells back to the same person for treating a diseased part. For the same purpose, stem cells are removed from the patient, harvested, cultured, and once again transplanted to the same person. The purpose of this method is to reduce the chances of rejection to the treatment by the body.

Furthermore, autologous cell therapy does not even require immunosuppression. The growing number of cancer patients have triggered a significant demand for autologous cell therapy. According to the research report, the global market projected to reach a valuation of US$23.7 bn by the end of 2024 as compared to US$3.8 bn in 2015. During the forecast period of 2016 and 2024, the global market is estimated to exhibit a CAGR of 21.9%.

Obtain Report Details @http://www.transparencymarketresearch.com/autologus-cell-therapy-market.html

Unmet Medical Needs and Cost-effectiveness of Autologous Cell Therapy Drives Demand

The global market is expected to grow due to the huge pool of unmet medical needs for cell based therapy, growing government support for cell-based research, and rising number of technological innovations in cell based therapies. Currently, cell therapy is considered a promising technique for several conditions such as neurological, orthopedic, oncology, and a wide range of autoimmune diseases. The ability of stem cells to transform into a cartilage, tendon, bone (osteoblast), and muscle has given this market a fresh lease of life.

The biggest advantages of autologous cells is the fact that it is relatively cost-effective, allows quick access to blood as it is derived from the patient, ensures easy method of production, and comes with the lowest threat of disease transfusion. All of these factors have been consistently boosting the demand for autologous cell therapy in recent years.

Grants to Continue R&D Keep North America in the Lead

On the basis of source, the global market is segmented into bone marrow and epidermis. Of these, the bone marrow segment is expected to prosper as compared to the other segment. By the end of 2024, the bone marrow segment is expected to reach a valuation of US$12.0 bn. Known as the hub of stem cell, the bone marrow segment is expected to grow against the backdrop of increasing number of bone marrow-based products being manufactured by the pharmaceutical industry. Furthermore, the extensive research and development activities for bone marrow-based stem cells is also expected to boost the growth of the market.

In terms of geography, the global autologous market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Of these North America is expected to dominate the global market in the coming years. The North America autologous Cell therapy market was valued at US$2.1 bn in 2015. Provision for grants from organizations such as CIRM, National Institutes of Health (NIH), and New York Stem Cell Science are expected to keep North America in the forefront in the coming few years.

For more information on this report, fill the form @http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=715

High Prevalence of Cancer Triggers Demand for Autologous Cell Therapy

The America Cancer Society states about a million people in the U.S. alone are diagnosed with various types of cancer with each passing years. The World Health Organization states that there will be a 30% rise in the number of cancer cases in the next decades. Furthermore, drastically changing lifestyles that are defined by the poor dietary choices and sedentary living are also expected to contribute the soaring number of cancer cases across the globe.

Statistics shared by International Agency for Research on Cancer (IARC) and WHO stated that the occurrence of cancer has been on the steady rise amongst the geriatric population. Furthermore, about 60% of the world’s new cancer cases are registered in developing regions of Asia, Africa, and Central America. All of these factors have triggered a huge demand for autologous cell therapy for treating cancer and managing the disease.

Debate over Ethics of Embryonic Stem Cells Creates Impediment

The heated debate over ethical issues of the killing of embryos after extraction of cells is the toughest challenge of the global autologous cell therapy market. Thus, the restriction on research and development activities pertaining to embryonic stems cells is anticipated to hamper the growth of the overall market. Furthermore, lack of reimbursement policies for those seeking cell therapy along with the high cost of treatment is also expected to restrict the scope for growth for the overall market.

This review is based on Transparency Market Research’s review, titled “Autologous Cell Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.